Literature DB >> 3686044

Impact of dose-intense chemotherapy on the development of permanent drug resistance.

A J Coldman1, J H Goldie.   

Abstract

Using a somatic mutation theory for drug resistance, dose intense regimens are shown to be superior in increasing the likelihood of no doubly resistant cells and in curing the tumor. Consideration of this model suggests that dose intensity of early chemotherapy cycles should be calculated separately and correlated with treatment outcome.

Entities:  

Mesh:

Year:  1987        PMID: 3686044

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  12 in total

1.  Dose-Dense Chemotherapy: Principles, Clinical Results and Future Perspectives.

Authors:  Marc L Citron
Journal:  Breast Care (Basel)       Date:  2008-08-20       Impact factor: 2.860

Review 2.  Neoadjuvant Dose-Dense and Dose-Intensified Chemotherapy in Breast Cancer - Review of the Literature.

Authors:  Mattea Reinisch; Beyhan Ataseven; Sherko Kümmel
Journal:  Breast Care (Basel)       Date:  2016-02-23       Impact factor: 2.860

3.  MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.

Authors:  W Oster; T Forsthuber; H H Hennekeuser; H Gamm; A Lindemann; G Schmitz; H G Fuhr; R Hinterberger; H Kreiter; W Thoenes
Journal:  Blut       Date:  1990-01

4.  Feasibility study of intraarterial vs intravenous cisplatin, BCNU, and teniposide combined with systemic cisplatin, teniposide, cytosine arabinoside, glycerol and mannitol in the treatment of primary and metastatic brain tumors.

Authors:  D J Stewart; Z Grahovac; H Hugenholtz; V DaSilva; M T Richard; B Benoit; G Belanger; N Russell
Journal:  J Neurooncol       Date:  1993-07       Impact factor: 4.130

5.  Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.

Authors:  J Walewski; J Romejko-Jarosińska; J Zwoliński; S Falkowski; P Siedlecki
Journal:  Med Oncol       Date:  1996-12       Impact factor: 3.064

6.  Drug resistance as a dynamic process in a model for multistep gene amplification under various levels of selection stringency.

Authors:  L E Harnevo; Z Agur
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.

Authors:  M Takada; M Fukuoka; Y Ariyoshi; K Furuse; H Niitani; K Ota; M Motomiya; K Hasegawa; K Tominaga; T Kuriyama
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.

Authors:  Sibylle Loibl; Tomas Skacel; Valentina Nekljudova; Hans Joachim Lück; Matthias Schwenkglenks; Thomas Brodowicz; Christoph Zielinski; Gunter von Minckwitz
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

Review 9.  Optimizing the future: how mathematical models inform treatment schedules for cancer.

Authors:  Deepti Mathur; Ethan Barnett; Howard I Scher; Joao B Xavier
Journal:  Trends Cancer       Date:  2022-03-09

Review 10.  Optimal Systemic Treatment for Early Triple-Negative Breast Cancer.

Authors:  Jenny Furlanetto; Sibylle Loibl
Journal:  Breast Care (Basel)       Date:  2020-06-02       Impact factor: 2.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.